Description

This Human IgG1 anti-c-Met DXd ADC is designed for targeted delivery of a potent topoisomerase I inhibitor payload to c-Met-expressing cells in in vitro and in vivo research applications. The antibody component specifically recognizes c-Met (hepatocyte growth factor receptor, HGFR), a receptor tyrosine kinase frequently overexpressed or dysregulated in a wide range of solid tumors, including gastric, lung, colorectal, and hepatocellular carcinomas. Targeting c-Met enables selective ADC internalization and intracellular payload delivery in tumor models with elevated receptor expression.

The antibody backbone retains a human IgG1 Fc region and is engineered to support efficient target engagement and receptor-mediated internalization. Following binding to surface c-Met, the ADC undergoes intracellular trafficking and lysosomal processing, enabling release of the DXd payload inside target cells. This format is suitable for studies evaluating ADC potency, intracellular processing, bystander activity, and c-Met-directed therapeutic mechanisms.

The GGFG-DXd linker-payload consists of a cleavable GGFG tetrapeptide linker attached to a derivative of exatecan, a potent DNA topoisomerase I inhibitor. This payload class is directly relevant to clinically validated DXd-based ADC platforms, including Enhertu (trastuzumab deruxtecan) and other investigational ADCs utilizing exatecan-derived payload chemistry. The membrane-permeable nature of DXd payloads may contribute to bystander killing activity in heterogeneous tumor models.

Each lot is manufactured under stringent quality control standards, including:

• Drug-to-antibody ratio (DAR) validation by both liquid chromatography-mass spectrometry (LC-MS) and hydrophobic interaction chromatography (HIC)
• Size exclusion chromatography (SEC) analysis confirming monomeric purity greater than 95%
• Reverse-phase HPLC (RP-HPLC) confirming free linker-payload below 1%
• Sterile filteration prior to dispensing
• Verification of low endotoxin levels

Applications:

• Evaluation of c-Met-targeted ADC cytotoxicity in cancer cell models
• Studies of receptor-mediated internalization and intracellular payload release
• Investigation of bystander killing effects associated with membrane-permeable DXd payloads
• In vitro and in vivo ADC pharmacology studies involving c-Met-expressing tumor models
• Comparative studies with clinically relevant DXd-based ADC platforms

Custom ADCs and ADC isotype controls are available upon request. Whether you need a specific antibody backbone, DAR target, or alternative linker-payload combination, our team can work with you to design and manufacture a conjugate matched to your experimental requirements. Contact us to discuss your needs.